Literature DB >> 31834570

Noninvasive Imaging for Assessment of the Efficacy of Therapeutic Agents for Hepatocellular Carcinoma.

Qian Liang1,2,3, Lingxin Kong1,2,3, Xu Zhu4, Yang Du5,6,7, Jie Tian8,9,10,11,12.   

Abstract

Morphological imaging techniques are typically used in the anti-cancer drug efficacy evaluation process. However, these techniques can evaluate the therapeutic efficacy only when the tumor shows anatomic changes-usually at later stages, when the therapeutic effects are poor. In contrast, molecular imaging allows noninvasive monitoring of tumor growth, assessment of drug metabolism, and evaluation of therapeutic efficacy at the molecular and cellular levels. Multimodality molecular imaging, which combines the advantages of various imaging modalities, provides even more comprehensive therapeutic efficacy assessment in preclinical and clinical studies. This review provides an overview of molecular imaging evaluation of therapeutic efficacy of the anti-tumor drugs in hepatocellular carcinoma (HCC) both in preclinical and clinical research, which holds great promise in guiding HCC treatment into the era of precision medicine.

Entities:  

Keywords:  Clinical trial; Hepatocellular carcinoma; Molecular imaging; Preclinical drug evaluation; Therapeutics

Mesh:

Substances:

Year:  2020        PMID: 31834570     DOI: 10.1007/s11307-019-01431-5

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  43 in total

Review 1.  High resolution X-ray computed tomography: an emerging tool for small animal cancer research.

Authors:  M J Paulus; S S Gleason; S J Kennel; P R Hunsicker; D K Johnson
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 2.  Molecular imaging in drug development.

Authors:  Jürgen K Willmann; Nicholas van Bruggen; Ludger M Dinkelborg; Sanjiv S Gambhir
Journal:  Nat Rev Drug Discov       Date:  2008-07       Impact factor: 84.694

Review 3.  Non-invasive molecular imaging for preclinical cancer therapeutic development.

Authors:  A C O'Farrell; S D Shnyder; G Marston; P L Coletta; J H Gill
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

4.  Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma.

Authors:  Cristina Grange; Simonetta Geninatti-Crich; Giovanna Esposito; Diego Alberti; Lorenzo Tei; Benedetta Bussolati; Silvio Aime; Giovanni Camussi
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

Review 5.  Non-invasive in vivo imaging in small animal research.

Authors:  V Koo; P W Hamilton; K Williamson
Journal:  Cell Oncol       Date:  2006       Impact factor: 6.730

Review 6.  Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis.

Authors:  Gustav J Strijkers; Ewelina Kluza; Geralda A F Van Tilborg; Daisy W J van der Schaft; Arjan W Griffioen; Willem J M Mulder; Klaas Nicolay
Journal:  Angiogenesis       Date:  2010-06       Impact factor: 9.596

7.  Imaging of murine liver tumor using microCT with a hepatocyte-selective contrast agent: accuracy is dependent on adequate contrast enhancement.

Authors:  Sharon M Weber; Karen A Peterson; Benjamin Durkee; Chen Qi; Mark Longino; Thomas Warner; Fred T Lee; Jamey P Weichert
Journal:  J Surg Res       Date:  2004-06-01       Impact factor: 2.192

8.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Jordi Bruix; Shukui Qin; Philippe Merle; Alessandro Granito; Yi-Hsiang Huang; György Bodoky; Marc Pracht; Osamu Yokosuka; Olivier Rosmorduc; Valeriy Breder; René Gerolami; Gianluca Masi; Paul J Ross; Tianqiang Song; Jean-Pierre Bronowicki; Isabelle Ollivier-Hourmand; Masatoshi Kudo; Ann-Lii Cheng; Josep M Llovet; Richard S Finn; Marie-Aude LeBerre; Annette Baumhauer; Gerold Meinhardt; Guohong Han
Journal:  Lancet       Date:  2016-12-06       Impact factor: 79.321

Review 9.  A molecular imaging primer: modalities, imaging agents, and applications.

Authors:  Michelle L James; Sanjiv S Gambhir
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

Review 10.  DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents.

Authors:  J P B O'Connor; A Jackson; G J M Parker; G C Jayson
Journal:  Br J Cancer       Date:  2007-01-09       Impact factor: 7.640

View more
  1 in total

1.  Preliminary Evaluation of Artificial Intelligence-Based Anti-Hepatocellular Carcinoma Molecular Target Study in Hepatocellular Carcinoma Diagnosis Research.

Authors:  Yuan Wang; Chao Wei; Xiangui Deng; Shudi Gao; Jing Chen
Journal:  Biomed Res Int       Date:  2022-09-19       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.